兴齐眼药:SQ-23082获临床试验批准,属2.1类

智通财经
Sep 11
【兴齐眼药:SQ-23082获临床试验批准,属2.1类】兴齐眼药公告,公司近日收到国家药品监督管理局签发的SQ-23082滴眼液《药物临床试验批准通知书》,审批同意开展临床试验。该药为化学药品2.1类改良型新药,拟用于过敏性结膜炎相关的眼痒的治疗,公司已完成药学及非临床药理毒理学等研究。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10